1. DISCUSSION: Discuss the neuropsychiatric safety findings presented for montelukast.

2. DISCUSSION: Discuss the current labeling for montelukast, including:
   
   a. Current Warnings and Precautions
   b. Request for Medication Guide and Boxed Warning

3. DISCUSSION: Discuss your recommendations for communication strategies
   
   a. Target audience
   b. Target organizations
   c. Modalities of communication